The Accuracy Paradox: Why BGM Is “Inaccurate” Until CGM Is Compared to It

After working with both BGM and CGM products for years, I’ve observed an interesting paradox.

In the BGM world, users say: “Your meter differs from another meter Brand X —Your meter must be inaccurate”

But in the CGM world, the same users say: “Your CGM differs from my blood glucose meter — so the CGM must be wrong.”

The device that was questioned yesterday becomes the absolute truth today.

Two Different Measurement Worlds

Here’s what we often forget.

A BGM (blood glucose meter) measures capillary blood glucose from a fingerstick sample.

A CGM measures glucose in interstitial fluid .

They are simply not measuring the same thing.

Interstitial glucose typically lags behind blood glucose by about 5–15 minutes, especially during rapid glucose changes (after meals, exercise, or hypoglycemia recovery).

So when glucose is rising or falling quickly, a gap between CGM and BGM is not necessarily a device error — it is a physiological phenomenon.

This is basic biology, not product quality.

Accuracy Standards Are Also Different

Even between two BGM devices, differences are allowed.

According to ISO 15197, 95% of BGM readings must fall within ±15% of a laboratory reference value.

That means two compliant meters can still show noticeable differences.

CGM systems, on the other hand, are typically evaluated using MARD (Mean Absolute Relative Difference), which measures overall accuracy across many data points — not single-point matching.

In other words:

The Real Value of CGM

CGM was not designed to replace a capillary reference at every minute.

It was designed to:

• Reveal glucose trends • Detect patterns • Provide early warnings • Improve time-in-range • Support long-term glycemic management

If the direction of glucose movement aligns, and alerts function appropriately, the system is doing what it was built to do.

Expecting perfect point-to-point alignment is expecting a trend-monitoring tool to behave like a spot-check device.

Why This Conversation Matters

Many still position CGM as “a more advanced blood glucose meter.”

That positioning is risky.

CGM is not a premium BGM.

It is a different category.

Whether you are a clinician, distributor, product manager, or patient, understanding the difference between point measurement and trend monitoring changes how CGM should be positioned and evaluated.

If we position it incorrectly, we create unrealistic expectations and unnecessary “accuracy debates.”

If we position it correctly — as a dynamic glucose management system — the conversation changes completely.

CGM does not simply introduce a new device. It introduces a new dimension — time.

And once time becomes part of clinical data, accuracy can no longer be judged at a single timestamp.

Perhaps the real shift isn’t technological. It’s conceptual.

Last question:

Should we still compare CGM readings with BGM values?

I think that comparing CGM to BGM is meaningful during the trust-building phase.

When someone first starts using CGM, it’s natural to validate the new system against a familiar reference. That comparison helps build confidence.

But once trust is established, the comparison framework must evolve.

CGM should not be judged solely by point-to-point matching.

It should be evaluated by trend consistency, alert performance, and its ability to improve time-in-range.

Otherwise, we risk using yesterday’s logic to assess tomorrow’s technology.